Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4573024 | 0.87 | NR1H2 (0.42) | NR1H2NR1H3CHRM4FAAH | |
| SCHEMBL4573185 | 0.85 | NR1H2 (0.64) | NR1H2NR1H3 | |
| SCHEMBL4573190 | 0.85 | NR1H2 (0.64) | NR1H2NR1H3 | |
| SCHEMBL25205050 | 0.81 | CHRM2 (0.45) | CHRM2CHRM1CHRM5CHRM3CHRM4 | |
| SCHEMBL25182095 | 0.81 | CHRM2 (0.45) | CHRM2CHRM1CHRM5CHRM3CHRM4 | |
| SCHEMBL25205047 | 0.81 | CHRM2 (0.45) | CHRM2CHRM1CHRM5CHRM3CHRM4 | |
| SCHEMBL31111518 | 0.81 | CHRM2 (0.57) | CHRM2CHRM1CHRM5CHRM3CHRM4 | |
| SCHEMBL4573282 | 0.81 | HSD11B1 (0.45) | HSD11B1CHRM4 | |
| SCHEMBL19096975 | 0.80 | CHRM2 (0.43) | NR1H2NR1H3CHRM2CHRM1CHRM5 | |
| SCHEMBL17375398 | 0.80 | CHRM2 (0.43) | NR1H2NR1H3CHRM2CHRM1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |